drughunter.com
3 minute read
Sep. 10, 2024

August Deals and Funding Rounds Recap

Loading...

twitterlinkedinemail

Other articles you may be interested in

Six Deals and Funding Rounds from July You May Have Missed

In case you missed anything while you were away on summer holiday, here’s a recap of six notable deals from July to get you up to speed.

July 2024 Molecule Roundup | 50 Molecules from July to Know

In this article, you'll find a curated selection of nearly 50 molecules from July that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

Drug Hunter 2023 M&A Review: Part 1 - Industry Overview

Drug Hunter has sifted through news articles, press releases, financial disclosures, SEC filings and more to bring you a roundup of 2023's biggest mergers and acquisitions (M&A) in the drug discovery world. In this 4-part series we will give you an open-access overview of the M&A landscape, and then for Drug Hunter members in the coming weeks, we will be providing in-depth coverage and analysis of the small molecule-focused (parts 2 & 3) and biologics-based deals (part 4). This premium content includes background on the targets, chemical/biological matter and clinical data driving these deals.

August 2024 Molecule Roundup | >70 Molecules to Know

In this article, you'll find a curated selection of >70 molecules from August that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

Drug Hunter 2023 M&A Review: Part 3 – Small Molecule-Focused Deals 10-1

Drug Hunter has sifted through news articles, press releases, financial disclosures, SEC filings, and more to bring you a roundup of 2023’s biggest mergers and acquisitions (M&A) in the drug discovery world. In part 3 of this 4-part series, we bring you the top-ranked small molecule-focused deals by value. Covering a range of targets and modalities, this article gives Drug Hunter members in-depth background and analysis of the hottest science opening checkbooks in 2023.